Skip to content

Assembly Biosciences ASMB Income Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$71.1M+121%$72.3M+154%$37.19M+31.3%$33.25M+54.8%$32.15M+148%
$64.86M+10.1%$64.81M+15.9%$61.84M+17.4%$58.77M+17.6%$58.91M+27.4%
$19.78M+10.6%$19.61M+8.9%$18.8M-15.0%$18M-18.4%$17.88M-20.6%
$84.64M+10.2%$84.42M+14.2%$80.64M+7.9%$76.77M+6.6%$76.79M+11.7%
-$43.45M+6.4%-$43.52M+13.9%-$44.63M+20.0%
$7.16M+42.0%$6M+7.6%$4.83M-20.5%$4.48M-16.4%$5.04M+12.2%
-$38.55M+5.5%-$38.96M+14.6%-$39.92M+22.3%
-$4.79+30.8%-$5.58+35.9%-$6.23+41.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What is Assembly Biosciences's revenue?
Assembly Biosciences (ASMB) generated $71.1M in revenue over the trailing twelve months, up 121.1% year over year.
Is Assembly Biosciences profitable?
Assembly Biosciences is not currently profitable: it reported a net loss of $37.3M over the trailing twelve months, a -103.6% net margin.
What is Assembly Biosciences's earnings per share?
Assembly Biosciences's diluted EPS over the trailing twelve months is $-3.76.
Where does Assembly Biosciences's income statement data come from?
Every line is extracted from Assembly Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.